Pace Diagnostics

Pace Diagnostics is an emerging biotechnology company focused on the research, development, licensing, manufacturing and marketing of cutting-edge diagnostics. Formed on the culmination of decades of basic and applied research, supported by grants and contracts from the US Federal Government.

Raised $2.5 million in seed investment; Won > $6 million in grants from US DoD, NIH, and NSF
Huge market size: min 3.1 billion USD tuberculosis & 20 billion USD lung cancer diagnostics in 2022
British Biocell International (BBI) is our manufacturing partner
Each year: 10 million tuberculosis infections & 2 million deaths; 1 billion smokers & 2 million lung cancer deaths
Our TB test is specifically developed to meet all WHO requirements for performance, cost and use
Our products - low cost, accurate, non-invasive, non-lab dependent lung cancer & tuberculosis tests
We have a portfolio of proprietary material, filed patents and licensed IPs
Our products have clear path to FDA clinical trials & are targeted to have CE approval by early 2022

Marianne Nguyen, Co-Founder
Mrs. Nguyen received her undergraduate and graduate training at Georgia Institute of Technology, UCI and UMass Amherst. She held senior leadership positions w/ Honeywell Safety Products, Ametek, Tyco and board member at various private ventures.

Lorne Matter, COO & Co-Founder
Mr. Mattner is an executive with a track record that includes building start up companies, both domestically and in Asia, fund raising and two successful exits. He earned his MBA and BS from the University of Southern California.

Hiep Hoa T Nguyen, President & Co-Founder
Dr. Nguyen is President & Chief Science Officer for several biotech companies that he co-founded. He received his BS in Chemistry & ChE, both summa cum laude. He received his PhD. in Chemistry/Biophysics from the California Institute of Technology.